Relationship of In Vitro Synergy and Treatment Outcome with Daptomycin plus Rifampin in Patients with Invasive Methicillin-Resistant Staphylococcus aureus Infections | Zendy

Warren E. Rose | Zendy; Andrew D. Berti | Zendy; Jacob B. Hatch | Zendy; Dennis G. Maki | Zendy

Open Access

Relationship of In Vitro Synergy and Treatment Outcome with Daptomycin plus Rifampin in Patients with Invasive Methicillin-Resistant Staphylococcus aureus Infections

Author(s) -

Warren E. Rose,

Andrew D. Berti,

Jacob B. Hatch,

Dennis G. Maki

Publication year - 2013

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00325-12

Subject(s) - daptomycin , checkerboard , staphylococcus aureus , antibiotics , methicillin resistant staphylococcus aureus , medicine , microbiology and biotechnology , antibacterial agent , staphylococcal infections , vancomycin , biology , bacteria , genetics

We report the findings of a study examining the relationship betweenin vitro daptomycin-rifampin synergy and the therapeutic outcome of 12 patients with complex deep methicillin-resistantStaphylococcus aureus (MRSA) infections treated for prolonged periods with this combination. Checkerboard synergy was found in nine cases and was 100% predictive of therapeutic success; absence of synergy was found in three cases, two of which were therapeutic failures (P = 0.045). No relationship was observed between synergy and outcome by time-kill assessment. Checkerboard synergy may predict clinical response to daptomycin plus rifampin for complex invasive MRSA infections requiring prolonged treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research